HOME >> BIOLOGY >> NEWS
Structure of key receptor unlocked; Related proteins will fall like dominoes

After two years of stubborn persistence, scientists at Johns Hopkins have determined the 3-D structure of part of a protein called HER3, which should speed efforts to interfere with abnormal growth and cancer.

"It took us more than two years to interpret the data and get HER3's structure," says Dan Leahy, Ph.D., a Howard Hughes Medical Institute investigator and a professor of biophysics in Hopkins' Institute for Basic Biomedical Sciences. "Now that we have it, it might take only weeks to figure out its relatives."

Reporting the structure in the Aug. 1 online version of Science, Leahy says finding out the shapes of the entire HER family of proteins, HER1, HER2 and HER4, will provide the first opportunity to rationally design new drugs to interfere with them, possibly preventing or treating select forms of cancer.

HER2, for example, is the target of the breast cancer treatment Herceptin, an antibody. But while it's an effective life-prolonging treatment in certain breast cancer patients, different strategies targeting HER2 might also prove effective. Having a protein's structure allows scientists to conceive new strategies and pursue new classes of drugs, says Leahy.

A focus of many scientists because of the proteins' involvement in cell growth, the HER family are receptors for "epidermal growth factor" (EGF) and other chemicals. Although the DNA sequences of HER proteins have been known for some time, technical problems dogged efforts to understand how the proteins are shaped, Leahy says.

"Until we know proteins' structures, we're very limited in figuring out how a molecule or possible drug might bind," says Leahy. "We now have a starting point to see how molecules binding to HER3 change its shape and turn it on."

Stuck in the cell membrane, each HER protein consists of three parts: a region outside the cell that recognizes and binds certain molecules; a region that anchors the protein in the cell membrane; and a re
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
6-Aug-2002


Page: 1 2

Related biology news :

1. Structure solved at Scripps shows how one human protein reduces potency of chemotherapy
2. Structure solved by Scripps scientists shows one way that body controls gene expression
3. Structure of a Nobel-prize winning molecule: Aquaporin
4. Structure of HIV-neutralizing antibody solved
5. Structure of key breast cancer receptor determined
6. Structure of cog at the hub of metabolism reveals anti-ageing function
7. Structure of pain-modulating enzyme described by scientists at the Scripps Research Institute
8. Structure reveals details of cells cargo-carriers
9. New Science Press launches Proteins: From Sequence to Structure
10. Third piece completes deadly puzzle: Structure of anthrax toxin offers clues to treatment
11. Structure of key protein involved in cancer, osteoporosis and foot-and-mouth disease finally solved

Post Your Comments:
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
Cached News: